In vitro analysis of combinatory effects of antifungals against highly resistant fungal pathogens

• Conditions: mucormycosisfusariosis; B48.7; Opportunistic mycoses

• Registration Number: DRKS00007593
• Lead Sponsor: Robert Koch Institut Berlin

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2014-12-05
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Proven/probable infection according to EORTC/MSG criteria by Fusarium spp. or mucormycetes

Exclusion Criteria

none

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Minimal inhibitory concentrations (MICs) of antifungals tested according to CLSI microdilution method (in vitro)

Secondary Outcome Measures

Name	Time	Method
Synergy effects of antifungal combinations in vitro